Stephan A. Grupp
Children's Hospital of Philadelphia · 797 works · 64,816 citations · h-index 105
Top works
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- Current concepts in the diagnosis and management of cytokine release syndrome
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges